Active Ingredients: Lenalidomide
Strength: 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg
Dosage Form: Capsules
Mechanism of Action: Angiogenic inhibitor
First Approval: US (Dec 27, 2005), EU (14 Jun, 2007)
Revenue
Revlimid (lenalidomide) is one of the key products of Bristol-Myers Squibb (BMS) that represent a significant percentage of the company’s total revenue. Sales of…
